PL373572A1 - Pochodne hemiasterliny i ich zastosowanie - Google Patents

Pochodne hemiasterliny i ich zastosowanie

Info

Publication number
PL373572A1
PL373572A1 PL03373572A PL37357203A PL373572A1 PL 373572 A1 PL373572 A1 PL 373572A1 PL 03373572 A PL03373572 A PL 03373572A PL 37357203 A PL37357203 A PL 37357203A PL 373572 A1 PL373572 A1 PL 373572A1
Authority
PL
Poland
Prior art keywords
hrmiasterlin
derivatives
hrmiasterlin derivatives
Prior art date
Application number
PL03373572A
Other languages
English (en)
Other versions
PL219737B1 (pl
Inventor
James J. Kowalczyk
Galina Kuznetsov
Shawn Schiller
Boris M. Seletsky
Mark Spyvee
Hu Yang
Original Assignee
Eisai Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co.Ltd. filed Critical Eisai Co.Ltd.
Publication of PL373572A1 publication Critical patent/PL373572A1/pl
Publication of PL219737B1 publication Critical patent/PL219737B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
PL373572A 2002-03-22 2003-03-21 Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny PL219737B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36659202P 2002-03-22 2002-03-22

Publications (2)

Publication Number Publication Date
PL373572A1 true PL373572A1 (pl) 2005-09-05
PL219737B1 PL219737B1 (pl) 2015-07-31

Family

ID=28675269

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373572A PL219737B1 (pl) 2002-03-22 2003-03-21 Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny

Country Status (18)

Country Link
US (5) US7192972B2 (pl)
EP (2) EP2374454B1 (pl)
JP (3) JP5042444B2 (pl)
KR (1) KR101208266B1 (pl)
CN (1) CN1633289A (pl)
AU (1) AU2003228354B8 (pl)
BR (1) BRPI0308606B8 (pl)
CA (1) CA2479764C (pl)
IL (2) IL163868A0 (pl)
MX (1) MXPA04009209A (pl)
NO (1) NO334803B1 (pl)
NZ (2) NZ555951A (pl)
PH (1) PH12013500123A1 (pl)
PL (1) PL219737B1 (pl)
RU (1) RU2342399C2 (pl)
TW (1) TWI332835B (pl)
WO (1) WO2003082268A2 (pl)
ZA (1) ZA200407611B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192972B2 (en) * 2002-03-22 2007-03-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7390910B2 (en) * 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
IL283717B (en) 2013-03-15 2022-09-01 Cancer Research Tech Llc Methods and compositions for gamma-glutamyl cycle modulation
DK3086815T3 (da) 2013-12-27 2022-05-23 Zymeworks Inc Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater
KR20160125361A (ko) * 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
CN114716506A (zh) 2015-01-30 2022-07-08 苏特罗生物制药公司 用于偶联和治疗的哈米特林（hemiasterlin）衍生物
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
US11179441B2 (en) 2017-01-06 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
PT3666787T (pt) 2017-08-10 2024-03-21 Sumitomo Pharma Co Ltd Conjugados anticorpo-fármaco que incluem um derivado da hemiasterlina
JP7202301B2 (ja) 2017-08-10 2023-01-11 住友ファーマ株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
JP7437328B2 (ja) * 2019-02-13 2024-02-22 住友ファーマ株式会社 多能性幹細胞の除去剤
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
WO2020166600A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 システイン残基を有するヘミアスタリン誘導体
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
CN114195684B (zh) * 2021-12-21 2023-10-20 马鞍山诺恩特医药科技有限公司 一种氨基保护基n-取代手性氨基酸的合成方法
AU2024310675A1 (en) * 2023-06-29 2025-10-09 Pinotbio, Inc. Novel hemiasterlin derivative and use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
DE4016994A1 (de) * 1990-05-26 1991-11-28 Bayer Ag Neue anhydro-statin-phosphonopyrrolidine und -piperidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5312831A (en) * 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
JPH073444A (ja) * 1993-06-17 1995-01-06 Mitsubishi Materials Corp 耐割損性のすぐれた半導体装置の誘電薄膜形成用スパッタリング焼結ターゲット材
JPH0873444A (ja) * 1994-09-02 1996-03-19 Fujisawa Pharmaceut Co Ltd ベンゾジアゼピン誘導体
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5661175A (en) * 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
EP0910572B1 (en) 1996-05-14 2005-04-27 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US5962487A (en) * 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
WO1999032589A1 (en) * 1997-12-19 1999-07-01 Unilever N.V. Olive oil containing food composition
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
WO1999065299A1 (en) * 1998-06-19 1999-12-23 Smithkline Beecham Corporation Compositions and methods for expansion of hematopoietic cells
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US7022677B1 (en) * 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
EP1158996A4 (en) * 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
US6737409B2 (en) * 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US7192972B2 (en) * 2002-03-22 2007-03-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DE10230874A1 (de) 2002-07-09 2004-01-22 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Tubulysinanaloga
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
AU2003294463A1 (en) 2002-11-21 2004-06-18 Wyeth Cells resistant to chemotherapeutic compounds and uses thereof
WO2006063135A2 (en) 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
AU2006244450A1 (en) 2005-05-05 2006-11-16 Eisai Co., Ltd. Unsolvated and host-guest solvated crystalline forms of (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-L-valyl)(methyl)amino)-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses

Also Published As

Publication number Publication date
JP5042444B2 (ja) 2012-10-03
PL219737B1 (pl) 2015-07-31
BRPI0308606B1 (pt) 2019-01-15
TW200407122A (en) 2004-05-16
US7528152B2 (en) 2009-05-05
IL163868A (en) 2011-11-30
EP2374454A1 (en) 2011-10-12
US8129407B2 (en) 2012-03-06
BRPI0308606B8 (pt) 2021-05-25
EP2374454B1 (en) 2016-05-11
CN1633289A (zh) 2005-06-29
JP2007332160A (ja) 2007-12-27
NO334803B1 (no) 2014-05-26
US20120309938A1 (en) 2012-12-06
CA2479764A1 (en) 2003-10-09
US20140309174A1 (en) 2014-10-16
WO2003082268A3 (en) 2004-09-23
IL163868A0 (en) 2005-12-18
US7192972B2 (en) 2007-03-20
WO2003082268A2 (en) 2003-10-09
NO20044526L (no) 2004-12-21
KR101208266B1 (ko) 2012-12-05
NZ555951A (en) 2009-01-31
EP1490054A2 (en) 2004-12-29
US20080051434A1 (en) 2008-02-28
AU2003228354A1 (en) 2003-10-13
NZ535139A (en) 2007-07-27
TWI332835B (en) 2010-11-11
US8633224B2 (en) 2014-01-21
RU2342399C2 (ru) 2008-12-27
ZA200407611B (en) 2008-02-27
KR20040091748A (ko) 2004-10-28
US20050239870A1 (en) 2005-10-27
RU2004131218A (ru) 2005-05-27
US20100063095A1 (en) 2010-03-11
JP2005530717A (ja) 2005-10-13
CA2479764C (en) 2013-07-30
AU2003228354B2 (en) 2010-02-11
JP2013166754A (ja) 2013-08-29
AU2003228354B8 (en) 2010-03-04
MXPA04009209A (es) 2004-11-26
BR0308606A (pt) 2005-04-26
HK1162948A1 (en) 2012-09-07
PH12013500123A1 (en) 2015-10-26

Similar Documents

Publication Publication Date Title
EP1539941A4 (en) ADZYMES AND THEIR USES
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
EG25683A (en) Benzoxazine derivatives and uses thereof
IL174479A0 (en) Hemiasterlin derivatives and uses thereof
GB0220214D0 (en) Compounds and their use
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
AU2003296369A8 (en) Imminoamines and preparation thereof
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0220776D0 (en) FOXP2 and uses thereof
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
AU2003300859A8 (en) Carrier-ligand fusions and uses thereof
GB0218031D0 (en) Compounds and their use
GB0220215D0 (en) Compounds and their use
GB0223293D0 (en) Arch - 1 and half; arch - 3